Precision medicine in 2026: What it means for complex disease development

Historically, many autoimmune conditions have relied on steroids and long-term immunosuppressionoften effective but burdened by side effects and relapse risk. Emerging programs are now exploring targeted immune interventions that aim to eliminate disease-driving B-cells/plasma cells and enable durable remission without continuous immunosuppression.^7,8

The modality pipeline is also diversifying beyond “classic” CAR-T, including dual-target CAR-T and CAR-T regulatory T-cell (CAR-Treg) approaches. In parallel, T-cell engagers are being evaluated as another precision tool to redirect immune activity with different logistics than autologous cell therapy.^6,9

How precision medicine is changing in 2026

In 2026, the “precision” mindset is expanding beyond tumor genomics into how complex diseases are developed and delivered spanning protocol strategy, site readiness, long-term follow-up and data governance. A clear example is autoimmune R&D shifting from broad immunosuppression toward targeted immune interventions, including autoimmune applications of CAR-T and T-cell engagers that were pioneered in oncology.^6,7,8

The shift is not only scientific; it is developmental. Programs require more precise patient identification, more specialized site capability and stronger expectations for risk-based quality, earlier toxicity mitigation strategies proportional oversight and data integrity as modalities move into later-stage development.^1,5

The stakeholder lenses

Patients and caregivers: they increasingly need clarity on outcomes that matter (e.g., function, fatigue, pain), what participation entails, and how safety is monitored both immediately and over the long term. Patient-friendly resources and support pathways can strengthen informed decision-making and engagement.^4,11,13

Clinicians/Rheumatologists: engagement with the medical community early through collaboration with rheumatology/immunology leaders and academic centers, with training focused on patient selection, safety monitoring, and coordination with specialized treatment or cell-handling pathways where relevant.^8,10

Medical professionals: they should use conferences, continuing medical education, and scientific symposia to build awareness ahead of key milestones; post-launch, emphasize long-term outcomes tracking and real-world evidence to sustain trust.^4,12

Sites: precision trials can increase burden via complex eligibility criteria, narrow recruitment windows, specialized handling, and higher data volume. Precision trials often require enhanced infrastructure, including apheresis capabilities, 24/7 emergency support, and access to hematology/oncology and neurological expertise specialist support to manage modality‑specific risks Standardized workflows and reduced system switching are increasingly strategic levers to protect site capacity and data quality.^4,16

Sponsors: they must integrate science, operations, and quality earlier because feasibility constraints, patient competition with established standard of care and protocol complexity can make or break precision programs. Fit-for-purpose endpoints and risk-based oversight help prioritize what matters most for participant safety and result credibility.^1,5

Regulators and ethics committees: the focus is proportionality, participant protection and reliability of results-especially when trials incorporate decentralized elements, multiple digital systems or real-world inputs.

Clear definitions of acceptable toxicity thresholds and confirmation that sites are capable of managing Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are increasingly central to regulatory review.

Modern GCP expectations increasingly support technological innovation while reinforcing data governance.^1,4,14

Risks, safety and regulatory expectations

In 2026, teams are operationalizing updated Good Clinical Practice expectations. ICH E6(R3) reinforces a Quality-by-Design mindset, proportionate risk-based approaches and expanded attention to data governance and computerized systems directly relevant to precision programs that rely on complex data streams and multi-system workflows.^1,2,5,15

For immune-redirecting therapies and other advanced modalities, long-term follow-up expectations and post-treatment monitoring plans are central to participant protection and long-term credibility.^11,12

Operational considerations: Site readiness and patient access

Precision-led development changes operations from execution to strategy. Feasibility often starts with two questions: can the right patients be identified fast enough, and can sites deliver the protocol without undue burden? Hybrid/decentralized elements can expand access, but add complexity unless interoperability, oversight and workflow design are addressed upfront.^4,1

For advanced therapies, readiness can also include specialized capabilities (training, care coordination, safety pathways) aligned to the modality’s risk profile. Patient-centric elements reduced travel, clearer communication and practical support—can improve retention and data quality over time.^4,12

Patient access is also a precision issue: narrow eligibility can unintentionally exclude populations unless planning includes outreach beyond traditional hubs and study models that can reach patients who cannot travel easily (travel distance, caregiver availability mandates).^4,14

What CROs should do to support precision medicine programs in 2026

• Stakeholder identification and early engagement

  Identify priority patient segments, physician leaders and advocacy groups early to inform development, access, and communication strategies.^10,13

• Education and ongoing communications

  Begin targeted education ahead of key milestones explainer materials/toolkits, webinars/scientific forums and patient-friendly resources and maintain continuous, coordinated communication with physicians and patients.^4,12

• Operational readiness and feasibility

  Site feasibility should extend beyond enrollment projections to include protocol walkthrough workshops that assess operational readiness and burden. CROs should support optimization of complex and adaptive trial designs, identify community ready sites and plan for long term safety registries extending up to 15 years where required.¹¹

• Transition to launch mode

  Where regulatory approval is anticipated, shift to launch mode, integrating media/press engagement, focused physician outreach and structured patient onboarding and support pathways.¹²

• Real-world follow-up and evidence generation

  In parallel, establish real-world infrastructure registries or data collection, safety and outcomes monitoring and ongoing patient support programs to support long-term use and confidence.^11,12,17

• Reduce site burden through standardization

  Prioritize consistent workflows, minimize system switching and invest in site enablement, because site capacity is increasingly a strategic constraint.⁴

• CRS & ICANS management algorithms

  Unified CRS grading templates aligned with American Society for Transplantation and Cellular Therapy (ASTCT), pre-approved steroid/tocilizumab escalation ladders, standard neurotoxicity assessment forms and pre-built ICU escalation triggers to improve efficiency.¹⁵

Closing thought

Precision medicine in 2026 is not only about targeting a molecule, it is about targeting the entire development pathway: the right patient strategy, the right site capability model, the right quality system and the right evidence plan. Teams that win are those that operationalize precision reliably, ethically and at scale.^1,14

In summary:

• Sites are constrained by complexity.
• Sponsors are constrained by scalability and differentiation.
• Regulators and ethics committees are balancing speed with long-term safety.
• CROs must evolve into operational integrators.
• Patients face access friction more than scientific uncertainty.

References

• International Council for Harmonisation (ICH). Guideline for Good Clinical Practice E6(R3), Step 4 Final Guideline (Adopted 06 Jan 2025). View source
• ICH. Good Clinical Practice – ICH E6(R3) Step 4 Presentation (23 Jan 2025). View source
• U.S. Food and Drug Administration (FDA). E6(R3) Good Clinical Practice: Guidance for Industry (Sept 2025). View source
• FDA. Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties (Sept 2024). View source
• FDA. Achieving Fit-for-Purpose Clinical Trial Quality (Clinical Investigator Training Course slides, 12 Dec 2024). View source
• Shah K, Leandro M, Cragg M, et al. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clinical and Experimental Immunology. 2024;217(1):15–30. View source
• Zhou J, Lei B, Shi F, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology. 2024. View source
• van Leuven SI, Duivenvoorden R. CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world? Rheumatology. 2024;63(5):1192–1194. View source
• Bulliard Y, Freeborn R, Uyeda MJ, et al. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. Frontiers in Immunology. 2024. View source
• Greco R, Alexander T, Del Papa N, et al. Innovative cellular therapies for autoimmune diseases: EBMT position statement and clinical practice recommendations. eClinicalMedicine. 2024;69:102476. View source
• FDA. Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry (Jan 2020). View source
• IQVIA. Long-term follow-up for gene therapies – innovative, patient-centered approaches (Insight Brief). View source
• Lupus Foundation of America. Data Suggests CAR-T Therapy Shows Promise for Lupus Treatment (29 Apr 2025). View source
• European Medicines Agency (EMA) / ACT EU. Revised ICH E6(R3) principles and Annex 1 published (14 Jan 2025). View source
• Internal: Welcome-to-the-International-Council-for-Harmonisation-(ICH)-E6(R3)-at-Fortrea.aspx (Fortrea SharePoint resource page).
• Internal: Advarra Veeva engagement deck V1.1 (Reducing site and patient burden; integrated site-centric solutions).
• Internal: IS_0021_CGT_CGT_Cell Gene Therapy_0524_HiRes.pdf (Cell & Gene Therapy clinical development solutions; LTFU operational model; RWE and post-approval planning).
• Internal: CT plus TCE experience slides_Feb2025.pptx (T-cell engager and cell therapy experience and indications).